- Home
- SLRX vs BDTX Comparison
SLRX vs BDTX Comparison
Compare SLRX & BDTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SLRX
- BDTX
- Stock Information
- Founded
- SLRX N/A
- BDTX 2014
- Country
- SLRX United States
- BDTX United States
- Employees
- SLRX N/A
- BDTX N/A
- Industry
- SLRX Biotechnology: Pharmaceutical Preparations
- BDTX Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- SLRX Health Care
- BDTX Health Care
- Exchange
- SLRX Nasdaq
- BDTX Nasdaq
- Market Cap
- SLRX 1.8M
- BDTX 132.5M
- IPO Year
- SLRX N/A
- BDTX 2020
- Fundamental
- Price
- SLRX $0.89
- BDTX $2.48
- Analyst Decision
- SLRX
- BDTX Strong Buy
- Analyst Count
- SLRX 0
- BDTX 6
- Target Price
- SLRX N/A
- BDTX $14.83
- AVG Volume (30 Days)
- SLRX 3.5M
- BDTX 1.4M
- Earning Date
- SLRX 08-08-2025
- BDTX 08-05-2025
- Dividend Yield
- SLRX N/A
- BDTX N/A
- EPS Growth
- SLRX N/A
- BDTX N/A
- EPS
- SLRX N/A
- BDTX 0.09
- Revenue
- SLRX N/A
- BDTX $70,000,000.00
- Revenue This Year
- SLRX N/A
- BDTX N/A
- Revenue Next Year
- SLRX N/A
- BDTX N/A
- P/E Ratio
- SLRX N/A
- BDTX $28.38
- Revenue Growth
- SLRX N/A
- BDTX N/A
- 52 Week Low
- SLRX $0.45
- BDTX $1.20
- 52 Week High
- SLRX $7.20
- BDTX $6.75
- Technical
- Relative Strength Index (RSI)
- SLRX 48.03
- BDTX 57.54
- Support Level
- SLRX $0.61
- BDTX $2.34
- Resistance Level
- SLRX $1.33
- BDTX $2.71
- Average True Range (ATR)
- SLRX 0.15
- BDTX 0.17
- MACD
- SLRX -0.00
- BDTX -0.02
- Stochastic Oscillator
- SLRX 34.12
- BDTX 58.93
About SLRX Salarius Pharmaceuticals Inc.
Salarius Pharmaceuticals Inc is a clinical-stage biopharmaceutical company focused on developing effective treatments for cancers with high, unmet medical needs. The company has focused on two classes of drugs that address gene dysregulation: targeted protein inhibitors and targeted protein degradation. Its Pipeline includes seclidemstat (SP-2577), a small molecular inhibitor, and SP-3164, a small molecular protein degrader.
About BDTX Black Diamond Therapeutics Inc.
Black Diamond Therapeutics Inc is a clinical-stage oncology company developing MasterKey therapies that target families of oncogenic mutations in patients with cancer. It is engaged in the discovery and development of small molecule, tumor-agnostic therapies. The company has one pipeline technology platform, namely Mutation-Allostery-Pharmacology, which is targeting mutations in cancer. Its drugs under the pipeline are BDTX-4933 and BDTX-1535.